You can buy or sell MEI Pharma and other stocks, options, ETFs, and crypto commission-free!
MEI Pharma, Inc. engages in the clinical development of novel therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Read More Its pipeline also consists of ME-401, a highly selective, oral PI3K delta inhibitor; voruciclib, an oral, selective CDK inhibitor; and ME-344, a novel mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Yahoo FinanceMay 9
MEI Pharma Reports Third Quarter Fiscal Year 2019 Results and Operational Highlights
SAN DIEGO, May 9, 2019 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its third quarter ended March 31, 2019. "As progress continues across our pipeline of four clinical-stage oncology candidates, including two in clinical studies that may support future submissions for FDA marketing approval, we are particularly excited with the expanding data set from the ME-401 intermittent dosing schedule as it conti...
Earnings Preview: MEI Pharma (MEIP) Q3 Earnings Expected to Decline
MEI Pharma (MEIP) is expected to deliver a year-over-year decline in earnings on higher revenues when i t report s results for the quarter ended March 2019. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
Expected Aug 29, After Hours